US Exchange Filings

Bio Green Med Solution Shareholders Approve Future NRG Merger and Financing Proposals

Bio Green Med shareholders approved key steps toward its business combination with Future NRG, while authorizing up to 3 billion shares and a potential 1-for-4 to 1-for-16 reverse split. The votes also give the company broad flexibility to raise capital after the transaction.

Bio Green Med Solution shareholders approved five proposals tied to the company’s planned business combination with Future NRG Sdn Bhd and related financing and capital changes. The votes authorize the share issuance for the transaction, a potential change of control, a larger pool of authorized shares, a reverse stock split and future securities offerings.

The meeting was held on Nov. 19. Of 6,622,794 shares eligible to vote, 4,935,383 were present or represented by proxy, equal to 74.52%.

Key details

  • Shares for the Future NRG transaction: Shareholders approved issuing Bio Green Med shares to Future NRG’s selling shareholders under the business combination agreement dated June 4. The proposal received 4,178,146 votes in favor and 66,327 against.

  • Issuance above Nasdaq’s 20% threshold and change of control: Shareholders also approved issuing more than 20% of the company’s outstanding shares in connection with the transaction and the associated change of control. The vote was 4,177,953 in favor and 66,355 against.

  • Authorized shares increased to 3 billion: Shareholders approved an amendment to raise the number of common shares the company is authorized to issue to 3 billion. The vote was 4,844,487 in favor and 90,335 against. This increases the company’s capacity to issue shares; it does not itself issue those shares.

  • Reverse split authorized at a ratio between 1-for-4 and 1-for-16: Shareholders approved a reverse stock split, with the board to choose the final ratio within that range. The vote was 4,894,944 in favor and 40,250 against. The approval gives the board authority to implement a split, but the final ratio and timing were not specified.

  • Future securities offerings approved for 24 months after the transaction: The company may, during the 24-month period following the transaction, sell common shares, warrants or other securities tied to its common stock in one or more financing transactions. The proposal received 4,177,871 votes in favor and 65,501 against. No financing amount, pricing or specific offering terms were provided.

What changes

The shareholder approvals clear the way for the company to issue shares under the Future NRG transaction and recognize the associated potential change of control. They also give the company expanded authorized-share capacity and permission to pursue future equity-linked financing. The reverse split is permitted but remains subject to the board’s choice of ratio. The vote results do not state that the business combination has closed.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.